Cyclopharm (ASX:CYC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cyclopharm (ASX:CYC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change in substantial shareholding from AEF
Chinese Consensus Names Technegas Preferred Lung Agent
Chinese medical bodies unanimously recommend Technegas as preferred lung ventilation agent
Cyclopharm 1H 2026 Results Webinar
CYC 1H2026 Results Summary
Cyclopharm reports record 1H2026 revenue of A$17.5m driven by 74% US growth and new US guidelines
Half Yearly Report and Accounts
Cyclopharm reports record half-year revenue driven by US growth; net loss widens amid investment
New US Lung Imaging Guidelines Name Technegas as Preferred A
New US Lung Imaging Guidelines Name Technegas® as Preferred Ventilation Agent
ausbiz TV Presentation